IOVANCE BIOTHERAPEUTICS, INC. Files 8-K
Ticker: IOVA · Form: 8-K · Filed: Aug 29, 2025 · CIK: 1425205
| Field | Detail |
|---|---|
| Company | Iovance Biotherapeutics, Inc. (IOVA) |
| Form Type | 8-K |
| Filed Date | Aug 29, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.000041666 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-statements, exhibits, company-history
TL;DR
IOVANCE BIOTHERAPEUTICS filed an 8-K for financial statements, no major news.
AI Summary
On August 29, 2025, IOVANCE BIOTHERAPEUTICS, INC. filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no specific material events or transactions detailed in the provided excerpt. The company was formerly known as Lion Biotechnologies, Inc., Genesis Biopharma, Inc., and FREIGHT MANAGEMENT CORP.
Why It Matters
This 8-K filing indicates routine reporting of financial statements and exhibits by IOVANCE BIOTHERAPEUTICS, INC., suggesting no immediate significant corporate events.
Risk Assessment
Risk Level: low — The filing appears to be routine and does not disclose any significant new risks or material events.
Key Players & Entities
- IOVANCE BIOTHERAPEUTICS, INC. (company) — Registrant
- Lion Biotechnologies, Inc. (company) — Former Company Name
- Genesis Biopharma, Inc (company) — Former Company Name
- FREIGHT MANAGEMENT CORP (company) — Former Company Name
- August 29, 2025 (date) — Date of Report
FAQ
What is the primary purpose of this 8-K filing for IOVANCE BIOTHERAPEUTICS, INC.?
The primary purpose of this 8-K filing is to report financial statements and exhibits.
What was IOVANCE BIOTHERAPEUTICS, INC. previously named?
IOVANCE BIOTHERAPEUTICS, INC. was formerly known as Lion Biotechnologies, Inc., Genesis Biopharma, Inc., and FREIGHT MANAGEMENT CORP.
On what date was this 8-K report filed?
This 8-K report was filed on August 29, 2025.
In which state is IOVANCE BIOTHERAPEUTICS, INC. incorporated?
IOVANCE BIOTHERAPEUTICS, INC. is incorporated in Delaware.
What is the business address of IOVANCE BIOTHERAPEUTICS, INC.?
The business address of IOVANCE BIOTHERAPEUTICS, INC. is 825 Industrial Road, Suite 100, San Carlos, CA 94070.
Filing Stats: 434 words · 2 min read · ~1 pages · Grade level 9.3 · Accepted 2025-08-29 16:06:17
Key Financial Figures
- $0.000041666 — h registered Common stock, par value $0.000041666 per value IOVA The Nasdaq Stock Marke
Filing Documents
- tm2524604d1_8k.htm (8-K) — 25KB
- tm2524604d1_ex99-1.htm (EX-99.1) — 59KB
- tm2524604d1_ex99-1img001.jpg (GRAPHIC) — 80KB
- tm2524604d1_ex99-1img002.jpg (GRAPHIC) — 436KB
- tm2524604d1_ex99-1img003.jpg (GRAPHIC) — 174KB
- tm2524604d1_ex99-1img004.jpg (GRAPHIC) — 183KB
- tm2524604d1_ex99-1img005.jpg (GRAPHIC) — 130KB
- tm2524604d1_ex99-1img006.jpg (GRAPHIC) — 124KB
- tm2524604d1_ex99-1img007.jpg (GRAPHIC) — 165KB
- tm2524604d1_ex99-1img008.jpg (GRAPHIC) — 102KB
- tm2524604d1_ex99-1img009.jpg (GRAPHIC) — 174KB
- tm2524604d1_ex99-1img010.jpg (GRAPHIC) — 171KB
- tm2524604d1_ex99-1img011.jpg (GRAPHIC) — 127KB
- tm2524604d1_ex99-1img012.jpg (GRAPHIC) — 178KB
- tm2524604d1_ex99-1img013.jpg (GRAPHIC) — 162KB
- tm2524604d1_ex99-1img014.jpg (GRAPHIC) — 143KB
- tm2524604d1_ex99-1img015.jpg (GRAPHIC) — 87KB
- tm2524604d1_ex99-1img016.jpg (GRAPHIC) — 209KB
- tm2524604d1_ex99-1img017.jpg (GRAPHIC) — 148KB
- tm2524604d1_ex99-1img018.jpg (GRAPHIC) — 74KB
- tm2524604d1_ex99-1img019.jpg (GRAPHIC) — 173KB
- tm2524604d1_ex99-1img020.jpg (GRAPHIC) — 155KB
- tm2524604d1_ex99-1img021.jpg (GRAPHIC) — 157KB
- tm2524604d1_ex99-1img022.jpg (GRAPHIC) — 180KB
- tm2524604d1_ex99-1img023.jpg (GRAPHIC) — 167KB
- tm2524604d1_ex99-1img024.jpg (GRAPHIC) — 153KB
- tm2524604d1_ex99-1img025.jpg (GRAPHIC) — 200KB
- tm2524604d1_ex99-1img026.jpg (GRAPHIC) — 149KB
- tm2524604d1_ex99-1img027.jpg (GRAPHIC) — 216KB
- tm2524604d1_ex99-1img028.jpg (GRAPHIC) — 237KB
- tm2524604d1_ex99-1img029.jpg (GRAPHIC) — 74KB
- tm2524604d1_ex99-1img030.jpg (GRAPHIC) — 120KB
- tm2524604d1_ex99-1img031.jpg (GRAPHIC) — 192KB
- tm2524604d1_ex99-1img032.jpg (GRAPHIC) — 76KB
- 0001104659-25-085650.txt ( ) — 7309KB
- iova-20250829.xsd (EX-101.SCH) — 3KB
- iova-20250829_lab.xml (EX-101.LAB) — 33KB
- iova-20250829_pre.xml (EX-101.PRE) — 22KB
- tm2524604d1_8k_htm.xml (XML) — 4KB
01
Item 8.01 Other Events. On August 29, 2025, Iovance Biotherapeutics, Inc. (the "Company") updated its corporate presentation that it uses for presentations at healthcare conferences and to analysts, current stockholders, and others. A copy of the Company's presentation that it intends to use at such events is attached as Exhibit 99.1 and is incorporated herein by reference.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Iovance Biotherapeutics, Inc., Corporate Presentation – August 2025 104 Cover Page Interactive Data File (embedded as Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 29, 2025 Iovance Biotherapeutics, Inc. By: /s/ Frederick G. Vogt Name: Frederick G. Vogt, Ph.D., J.D. Title: Interim CEO, President, and General Counsel